🔥Handover Heatwave: Hot Med News Only!

Welcome to the coldest summer of the rest of your life 😳

All thanks to climate change, Zara’s never-ending midnight sun

But no matter the weather, we’ll be here. Like tardigrades after the sun explodes.
(Which at this rate might be any day now)

But first, the hottest Handover of the year🔥

👋 Happy Friday. Here’s what we got:

If you want to read any previous editions of The Handover, you can on our website.

While the nation waits for removal vans to pull up at Downing Street, the microbiology community is facing its own leadership challenge. 

With several of our sacred local guidelines heading for an electoral wipeout 😬

Because when it comes to treating Staph. Aureus bacteraemia, flucloxacillin is the ultimate, uninspiring incumbent. 
It isn't flashy, but has been seen as the serious option; able to steady the ship without rocking the boat.

We know it works well enough, so why roll the dice on alternatives? 

But the events of this week remind us that sometimes, you just need to try something new. 

And when it comes to this infection, the stakes couldn’t be higher.
Even with modern care, Staph. aureus bacteraemia has a 90-day mortality of 20-30%, and kills over 1 million people across the globe each year.

These sticky grapes of wrath can infect joints, destroy heart valves, or cause agonising abscesses. 

A problem of this scale needs a solution to match …

And luckily, there’s a team up to the task.

The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is a large-scale, international clinical trial, designed to revolutionise how S. aureus bacteraemia is treated globally. 

Rather than running separate trials, SNAP uses a flexible model to test multiple drugs at the same time.

Not only that, it looks at three different antibiotic resistance profiles;

And this week, two papers from this trial have broken through, each telling us to reconsider boring old flucloxacillin in different clinical contexts.

The first paper, published in The Lancet, looked at benzylpenicillin vs. flucloxacillin in cases of PSSA bacteraemia;

And paper number two, published in The New England Journal of Medicine, put cefazolin up against flucloxacillin in MSSA bacteraemia using the same metrics;

So the papers show that the alternative antibiotic was both more effective and safer than flucloxacillin.

In fact, the risk of AKI from flucloxacillin was felt to be so large that trial recruitment was terminated early!

(That’s what I call a landslide defeat…)

Now SNAP is an unblinded, open-label trial, so the risk of bias is ever-present.
And in real life, information about antibiotic sensitivity can take precious time to acquire.

But it's hard to fool truly objective outcomes like 90-day all-cause mortality or lab-measured renal function.

The electorate has spoken; it’s time for a new anti-microbial coalition to take over.

Characters: Chubby Charlie, Mum, Dr Dhokter 

Act 1

Scene 1: GP Clinic

[Enter Chubby Charlie and Mum. Charlie with a 12-pack of Kinder Happy Hippos. Mum holding 6 wrappers] 

Dr Dhokter reviews Charlie's notes – 

Age: 12 years old.
BMI: 36 kg/m²
PMH: SUFE, T2DM, Idiopathic Intracranial Hypertension and Obstructive Sleep Apnea that wakes the neighbours… 

Lifestyle Advice? Failed
NHS Healthy Plate? Has it ever worked?
Weight Loss Bootcamp? Biggest Loser Kids cancelled after season 1

[Charlie scoffs Hippo 7,8 and 9 in his mouth simultaneously] 

Mum: “Doctor, thank you so much for seeing us today. I just don’t know what to do with him. We stopped buying his regular chocolates, and we only buy the ones with extra protein. That’s good, isn’t it?”

Oh dear… 

Dr Dhokter: "Right... let's see what the evidence says."

Often, it’s safe to assume that a child will grow out of their baby fat.
But when it’s causing serious complications? It may be time to call in the cavalry. 

What are your options?
Whilst it would be pretty questionable to conduct bariatric surgery on a 13-year-old, there are some pharmacological options actually used on kids.

This study, published in JAMA Paediatrics, took a jab at comparing the effectiveness of pharmacotherapies (like Ozempic) vs lifestyle treatments and their combination. 

And just to be sure what they found was valid, the study they conducted was the mother-of-all-research, a meta-analysis and systematic review.

These researchers searched through hundreds of papers and landed on 42 relevent RCT’s, that included 3,835 children (median age 14.5 years). 

A variety of interventions were analysed, including:

Primary outcome measures: BMI changes and BMI z-score(the most important relevant BMI system for paeds)

Secondary outcome measure: Waist circumference (WC), fat mass (FM), and lean mass (LM).

Ready to hear what they found out? Let’s break it down in a numbered list for you.

Some interesting findings indeed. Looks like we have quite a few options for Charlie to choose from…

It still feels uncomfortable to say out loud: some children with obesity may benefit from anti-obesity medication. As our understanding of obesity evolves, perhaps our instincts about how it should be treated need to evolve too.

📉 Babe, Wake Up, Competition Ratios Just Plummeted for UK Grads

Speciality training just became a hell of a lot less competitive for UK graduates 👀

NHS England has released stats showing competition rations have effectively halved following the introduction of the Medical Training Prioritisation Act in March.

There were still a staggering 38,000 applications for just 9,520 speciality training posts starting this August (around 4 applicants per place), but prioritising UK grads and doctors with significant NHS experience* reduced the effective competition ratio for priority applicants to roughly just 2:1.

*Following a fierce debate, this was defined as 5 years of work in the NHS, as opposed to 2. Controversial.

It’s tough to name a more impactful move as far as competition ratios are concerned: just 163 non-priority applicants accepted training posts this year, down from over 2,100 in 2025.

For the first time ever, every single GP training post was filled by UK or prioritised graduates.

A  Department of Health spokesperson has confirmed the new law has “slashed competition for roles, putting an end to the jobs crisis resident doctors have been calling on us to fix.” 

💊 Pressing Pause on Pancreatic Destruction in Type 1 Diabetics

100 years ago, type 1 diabetes was a death sentence.
50 years ago, we only had pig and cow insulin.
25 years ago, automatic insulin pumps were the stuff of dreams.

Now, we might be able to change the disease itself 🫳🎤

Teplizumab, the first disease-modifying treatment for type 1 diabetes, has been recommended by NICE for NHS use. 

It's not a cure, and it won't stop the disease altogether. Instead, it presses pause.

By dampening the immune system's attack on the insulin-producing cells in the pancreas, it’s been shown in trials to delay the onset of symptomatic disease by an average of 32 months.

That might not sound like much, but imagine being a kid with a new diagnosis. That’s a whole 3 years without insulin injections, hypos or the daily mental load of diabetes.

Around 1,100 people are expected to be eligible in the first year. 

Identification remains a challenge as patients lack symptoms in this early disease stage. Screening programmes are already in progress to help fix this.

👂 Martha’s Rule Makes Maternity Debut

The government has announced that Martha's Rule is being rolled out to every maternity setting in England, allowing patients access to an urgent second clinical opinion if they're worried.

The rule is named after 13-year-old Martha Mills, who died from sepsis in 2021 after repeated concerns from her parents weren't acted on.

Since its introduction in adult hospital wards, the rule has triggered more than 2,100 escalations, with over 600 leading to an escalation in level of care.

This move comes after the Ockenden review in Nottingham, which found repeated systemic failures across multiple maternity centres.

The government has also announced tougher accountability measures, including possible prison sentences of up to two years, for NHS staff who deliberately cover up serious care failings.

📖 Handover Read of The Week

This week’s read comes from r/DoctorsUK, where a user argues that current doctor pay is actually more than fair 👀 …

Plenty of strong opinions in the comments, as you might expect. A good mix of takes and well worth a read 👉 here.

Handover Over 🫡

If you liked it, tell your mates
(forward along, please. It only takes 12 seconds, making this took 12 hours.)
If you hated it, tell your enemies.

Would you look at that… A Friday Handover… on a Saturday morning?

This was not an accident. You see, when the Handover started, we didn’t pick Friday evening because it was the best time to send out medical news.

We simply spun a wheel with dates on it and picked the first lucky day of the week. Then ran with it ever since.

We’ve researched so many experiments that we wanted to run one of our own. Are other days of the week better than Friday? Let us know what you’d like in the poll below.

Enjoy the rest of your weekend!